Across its top 20 institutional holders, AEON's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 12/100, avg. turnover score 31/100).

Quarterly Activity

Recent Activity

+$2.6M

Total Buy Value

$160.7K

Total Sell Value

New buy6

Trim2

Add4

Sold out5

Net Buyers

Net Sellers

Smart Money Convergence

AEON does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-15

2026-07-15

AEON Biopharma raised approximately $12.2 million in net proceeds through a public offering that closed on July 15, 2026. The offering included shares of common stock and pre-funded warrants, each accompanied by milestone warrants. The company intends to use the funds for working capital and to support biosimilar testing of its drug ABP-450.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

00791X209

FAQ

Who are the top institutional investors holding AEON BIOPHARMA INC (AEON)?

Major stakeholders currently include Dauntless Investment Group, LLC ($2.5M), Vanguard Capital Management LLC ($89.2K), Geode Capital Management, LLC ($85.8K). Based on the latest 13F filings, there are a total of 24 tracked investment funds and institutions maintaining positions in AEON.

What is the overall institutional sentiment toward AEON recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $1.1M, driven by 10 managers accumulating shares while 7 reduced their exposure.

Which institutions have been selling or reducing their AEON positions?

In the latest period, 2 funds trimmed their holdings, and 5 managers completely exited their positions. The aggregate reported sell value was $160.7K.

Are there any notable investors adding AEON to their portfolios?

Yes, buying activity remains notable. 6 institutions opened new positions in {ticker}, and 4 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.6M.